Join
Live feed
·
PRReleasevia Quantisnow
BioAtla Inc. logo

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

ByQuantisnow·Wall Street's wire, on your screen.
BCAB· BioAtla Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BCAB (BioAtla Inc.) and more on Quantisnow.